4D Molecular Therapeutics, Inc.

NasdaqGS:FDMT Stock Report

Market Cap: US$245.0m

4D Molecular Therapeutics Management

Management criteria checks 2/4

4D Molecular Therapeutics' CEO is David Kirn, appointed in Sep 2013, has a tenure of 11.25 years. total yearly compensation is $10.29M, comprised of 5.8% salary and 94.2% bonuses, including company stock and options. directly owns 3.59% of the company’s shares, worth $8.79M. The average tenure of the management team and the board of directors is 3.2 years and 4.1 years respectively.

Key information

David Kirn

Chief executive officer

US$10.3m

Total compensation

CEO salary percentage5.8%
CEO tenure11.3yrs
CEO ownership3.6%
Management average tenure3.2yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Nov 24
Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 04

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Aug 10
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Jul 19

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Sep 29
We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

Aug 11

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Jun 11
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

CEO Compensation Analysis

How has David Kirn's remuneration changed compared to 4D Molecular Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$143m

Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$105m

Dec 31 2023US$10mUS$597k

-US$101m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$3mUS$586k

-US$107m

Sep 30 2022n/an/a

-US$105m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$5mUS$570k

-US$71m

Sep 30 2021n/an/a

-US$67m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$702kUS$451k

-US$57m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$554kUS$430k

-US$49m

Sep 30 2019n/an/a

-US$35m

Jun 30 2019n/an/a

-US$21m

Mar 31 2019n/an/a

-US$15m

Dec 31 2018US$546kUS$396k

-US$10m

Compensation vs Market: David's total compensation ($USD10.29M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Kirn (62 yo)

11.3yrs

Tenure

US$10,286,808

Compensation

Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013. Dr. Kirn...

Leadership Team

NamePositionTenureCompensationOwnership
John Milligan
Executive Chairman4.3yrsUS$581.44k0.22%
$ 530.0k
David Kirn
Co-Founder11.3yrsUS$10.29m3.59%
$ 8.8m
Fariborz Kamal
President & COO4.8yrsUS$4.54m0.013%
$ 31.5k
Noriyuki Kasahara
Chief Scientific Officerless than a yearUS$488.91kno data
Robert Kim
Chief Medical Officer2.2yrsUS$3.96m0.0023%
$ 5.5k
Theresa Janke
Co-Founder & Chief of Staff11.9yrsUS$2.70mno data
Uneek Mehra
Chief Financial & Business Officer1.3yrsno datano data
Scott Bizily
Chief Legal Officer & Corporate Secretary3.3yrsno data0.015%
$ 35.9k
An Song
Chief Development Officer3.1yrsno datano data
Alan Cohen
Senior VP & Therapeutic Area Head of Pulmonologyno datano datano data
Christopher Simms
Chief Commercial Officerless than a yearno datano data
Karen Carothers
Controller8.3yrsno datano data

3.2yrs

Average Tenure

62yo

Average Age

Experienced Management: FDMT's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Milligan
Executive Chairman4.3yrsUS$581.44k0.22%
$ 530.0k
David Kirn
Co-Founder11.3yrsUS$10.29m3.59%
$ 8.8m
Charles Theuer
Independent Director9yrsUS$352.62k0.070%
$ 171.5k
Susannah Gray
Independent Director4.4yrsUS$352.62k0%
$ 0
Paul Utz
Member of Scientific Advisory Boardless than a yearno datano data
Richard Moss
Member of Scientific Advisory Boardless than a yearno datano data
Jacob Chacko
Independent Director5.8yrsUS$352.62k0%
$ 0
Shawn Tomasello
Independent Director4.1yrsUS$345.12k0%
$ 0
Daniel Takefman
Member of Scientific Advisory Boardless than a yearno datano data
Amit Gaggar
Member of Scientific Advisory Boardless than a yearno datano data
Nancy Miller-Rich
Independent Director4.1yrsUS$340.12k0%
$ 0
Arshad Khanani
Chair of Ophthalmology Advisory Boardless than a yearno datano data

4.1yrs

Average Tenure

62.5yo

Average Age

Experienced Board: FDMT's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 00:12
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

4D Molecular Therapeutics, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research
Daniel GiraldoBofA Global Research